🔎 Trials Near Me

Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Distaarikii Koloombiyaa › Washington

Qorannoo klinikaalii Kansaar Onnee Triple-Negative Washington, DC keessatti

Qorannoo 11 Kansaar Onnee Triple-Negative f Washington fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

Namoota walitti qabaa jiraQorannoo ilaalaa
  • National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07619534

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Namoota walitti qabaa jiraSadarkaa 3
  • Washington Hospital Center ( Site 0098), Washington D.C.
  • Holy Cross Hospital ( Site 0091), Silver Spring · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06841354

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Namoota walitti qabaa jiraSadarkaa 3
  • Holy Cross Hospital ( Site 0069), Silver Spring · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06393374

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Georgetown University Medical Center, Washington D.C.
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT05983432

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Namoota walitti qabaa jiraSadarkaa 3
  • MedStar Georgetown University Hospital, Washington D.C.
  • MedStar Washington Hospital Center, Washington D.C.
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT05633654

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

Namoota walitti qabaa jira
  • National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 21-Hag-2026 · NCT07067138

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Normunity Investigational Site, Washington D.C.
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07182149

Study of XB010 in Subjects With Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Georgetown University Medical Center, Washington D.C.
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Wax-2026 · NCT06545331

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Namoota walitti qabaa jiraSadarkaa 2
  • National Institute of Health Clinical Center, Bethesda · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Wax-2026 · NCT05660083

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • Georgetown University Medical Center, Washington D.C.
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT01042379

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Namoota walitti qabaa jiraQorannoo ilaalaa
  • George Washington University, Washington D.C.
Umuriin 18 fi ol · Dubartoota · Haaromfame 07-Ama-2025 · NCT06230185

Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti

Qorannoo biroo Washington keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.